 Dara Aisner
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 59 | 2022 | 2199 | 5.270 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 39 | 2022 | 993 | 3.670 |
Why?
| | Genetic Testing | 8 | 2019 | 365 | 2.580 |
Why?
| | Pathology, Molecular | 7 | 2019 | 27 | 2.440 |
Why?
| | ErbB Receptors | 17 | 2019 | 553 | 2.250 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 203 | 2.230 |
Why?
| | Mutation | 34 | 2022 | 3403 | 1.910 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 96 | 1.880 |
Why?
| | Protein Kinase Inhibitors | 22 | 2021 | 857 | 1.760 |
Why?
| | High-Throughput Nucleotide Sequencing | 10 | 2020 | 419 | 1.690 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 715 | 1.540 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 448 | 1.520 |
Why?
| | Proto-Oncogene Proteins B-raf | 12 | 2018 | 197 | 1.470 |
Why?
| | Biomarkers, Tumor | 16 | 2021 | 1060 | 1.310 |
Why?
| | Neoplasms | 10 | 2019 | 2079 | 1.310 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 160 | 1.290 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 238 | 1.240 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 277 | 1.220 |
Why?
| | Antineoplastic Agents | 15 | 2019 | 2037 | 1.210 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 72 | 1.110 |
Why?
| | Drug Resistance, Neoplasm | 12 | 2022 | 681 | 1.080 |
Why?
| | Gene Rearrangement | 13 | 2019 | 170 | 0.970 |
Why?
| | Adenocarcinoma | 9 | 2018 | 814 | 0.960 |
Why?
| | Brain Neoplasms | 10 | 2018 | 983 | 0.940 |
Why?
| | Ganglioglioma | 4 | 2014 | 34 | 0.890 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 410 | 0.840 |
Why?
| | Precision Medicine | 4 | 2018 | 296 | 0.830 |
Why?
| | Molecular Targeted Therapy | 10 | 2018 | 380 | 0.820 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 97 | 0.760 |
Why?
| | Pyrazoles | 10 | 2018 | 400 | 0.760 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 6 | 0.760 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.760 |
Why?
| | Astrocytoma | 3 | 2015 | 111 | 0.740 |
Why?
| | Insurance Coverage | 1 | 2020 | 219 | 0.710 |
Why?
| | Prognosis | 12 | 2019 | 3550 | 0.680 |
Why?
| | Humans | 105 | 2022 | 115146 | 0.670 |
Why?
| | Neoplasm Metastasis | 9 | 2022 | 611 | 0.670 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 340 | 0.670 |
Why?
| | Computational Biology | 3 | 2019 | 481 | 0.660 |
Why?
| | Laboratory Proficiency Testing | 1 | 2016 | 7 | 0.620 |
Why?
| | RNA | 5 | 2019 | 779 | 0.610 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2015 | 54 | 0.560 |
Why?
| | Immunohistochemistry | 9 | 2019 | 1784 | 0.560 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 82 | 0.540 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 466 | 0.540 |
Why?
| | ras Proteins | 5 | 2015 | 146 | 0.520 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 806 | 0.510 |
Why?
| | Smoking | 3 | 2018 | 1596 | 0.500 |
Why?
| | Pyridines | 8 | 2016 | 499 | 0.490 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 156 | 0.480 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1394 | 0.460 |
Why?
| | Colorectal Neoplasms | 2 | 2020 | 595 | 0.450 |
Why?
| | Neoplasm Staging | 11 | 2018 | 1219 | 0.450 |
Why?
| | Aged, 80 and over | 15 | 2020 | 6845 | 0.430 |
Why?
| | Telomerase | 7 | 2002 | 223 | 0.430 |
Why?
| | S100 Proteins | 2 | 2014 | 41 | 0.430 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 358 | 0.430 |
Why?
| | Male | 48 | 2022 | 60969 | 0.400 |
Why?
| | Aged | 27 | 2020 | 20309 | 0.390 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 307 | 0.390 |
Why?
| | Female | 46 | 2022 | 63296 | 0.390 |
Why?
| | Sulfones | 3 | 2015 | 104 | 0.380 |
Why?
| | Glycine | 3 | 2015 | 157 | 0.370 |
Why?
| | Curriculum | 1 | 2016 | 848 | 0.370 |
Why?
| | Genomics | 3 | 2019 | 518 | 0.370 |
Why?
| | Pyrimidines | 3 | 2018 | 408 | 0.360 |
Why?
| | Middle Aged | 34 | 2020 | 28958 | 0.350 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 74 | 0.350 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 420 | 0.340 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 52 | 0.330 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 79 | 0.320 |
Why?
| | Oncogene Fusion | 2 | 2019 | 10 | 0.320 |
Why?
| | Gene Dosage | 2 | 2018 | 134 | 0.320 |
Why?
| | Exons | 5 | 2019 | 305 | 0.320 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 58 | 0.310 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 155 | 0.310 |
Why?
| | Melanoma | 2 | 2020 | 718 | 0.310 |
Why?
| | Treatment Outcome | 11 | 2019 | 9218 | 0.310 |
Why?
| | Oncogenes | 3 | 2016 | 108 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2197 | 0.290 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 13 | 0.290 |
Why?
| | Immunotherapy | 5 | 2022 | 459 | 0.290 |
Why?
| | Adult | 29 | 2022 | 32202 | 0.280 |
Why?
| | Epithelioid Cells | 2 | 2015 | 8 | 0.280 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 328 | 0.270 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 558 | 0.250 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1922 | 0.250 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 2891 | 0.240 |
Why?
| | Survival Analysis | 4 | 2021 | 1410 | 0.240 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 64 | 0.230 |
Why?
| | Gene Fusion | 2 | 2018 | 22 | 0.220 |
Why?
| | Glioblastoma | 2 | 2015 | 247 | 0.220 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 30 | 0.220 |
Why?
| | Patient Selection | 4 | 2018 | 707 | 0.220 |
Why?
| | Young Adult | 12 | 2019 | 11032 | 0.220 |
Why?
| | Pheochromocytoma | 1 | 2022 | 51 | 0.210 |
Why?
| | Meningioma | 1 | 2022 | 69 | 0.210 |
Why?
| | Cell Proliferation | 7 | 2017 | 2373 | 0.210 |
Why?
| | Biopsy | 4 | 2018 | 1050 | 0.210 |
Why?
| | Trastuzumab | 1 | 2021 | 104 | 0.210 |
Why?
| | Carbazoles | 1 | 2021 | 95 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1217 | 0.210 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 15 | 0.200 |
Why?
| | United States | 9 | 2020 | 12598 | 0.200 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 65 | 0.200 |
Why?
| | Government Regulation | 1 | 2020 | 48 | 0.200 |
Why?
| | Pathology, Clinical | 2 | 2017 | 36 | 0.200 |
Why?
| | Piperidines | 1 | 2021 | 182 | 0.190 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 206 | 0.190 |
Why?
| | Stakeholder Participation | 1 | 2020 | 67 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 146 | 0.190 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 55 | 0.190 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 28 | 0.190 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 339 | 0.190 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 40 | 0.180 |
Why?
| | Smad4 Protein | 1 | 2019 | 37 | 0.180 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 57 | 0.180 |
Why?
| | Acrylamides | 2 | 2017 | 43 | 0.180 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 31 | 0.180 |
Why?
| | Multigene Family | 1 | 2019 | 202 | 0.180 |
Why?
| | Pyridazines | 1 | 2018 | 57 | 0.180 |
Why?
| | Pathologists | 1 | 2018 | 12 | 0.180 |
Why?
| | Genetic Markers | 1 | 2019 | 350 | 0.170 |
Why?
| | Thromboembolism | 1 | 2018 | 101 | 0.170 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 23 | 0.170 |
Why?
| | Database Management Systems | 1 | 2018 | 49 | 0.170 |
Why?
| | Skin Neoplasms | 2 | 2020 | 763 | 0.170 |
Why?
| | Gene Frequency | 1 | 2019 | 431 | 0.170 |
Why?
| | Piperazines | 2 | 2018 | 328 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 178 | 0.170 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 573 | 0.170 |
Why?
| | Genetic Association Studies | 1 | 2019 | 345 | 0.170 |
Why?
| | Quinazolines | 3 | 2014 | 245 | 0.170 |
Why?
| | Intraoperative Care | 1 | 2017 | 49 | 0.170 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 135 | 0.160 |
Why?
| | Smokers | 1 | 2018 | 146 | 0.160 |
Why?
| | Indoles | 2 | 2017 | 348 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 135 | 0.160 |
Why?
| | Medical Informatics | 1 | 2018 | 100 | 0.160 |
Why?
| | Gene Deletion | 1 | 2019 | 382 | 0.160 |
Why?
| | Imidazoles | 1 | 2018 | 264 | 0.160 |
Why?
| | Chloroquine | 1 | 2017 | 65 | 0.160 |
Why?
| | Coculture Techniques | 1 | 2017 | 204 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 83 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 281 | 0.150 |
Why?
| | Neoadjuvant Therapy | 1 | 2018 | 290 | 0.150 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 17 | 0.150 |
Why?
| | Liver Neoplasms | 3 | 2015 | 463 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2017 | 161 | 0.150 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 21 | 0.150 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 149 | 0.150 |
Why?
| | Sulfonamides | 2 | 2017 | 455 | 0.150 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 53 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 65 | 0.150 |
Why?
| | Immunity, Humoral | 1 | 2016 | 103 | 0.150 |
Why?
| | Codon | 1 | 2016 | 90 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 63 | 0.150 |
Why?
| | RNA, Messenger | 4 | 2018 | 2835 | 0.140 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 74 | 0.140 |
Why?
| | Medicare | 1 | 2020 | 668 | 0.140 |
Why?
| | Laboratories | 1 | 2016 | 100 | 0.140 |
Why?
| | Oncogene Proteins | 1 | 2015 | 63 | 0.140 |
Why?
| | Hamartoma | 1 | 2015 | 18 | 0.140 |
Why?
| | Fatal Outcome | 1 | 2016 | 314 | 0.140 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 287 | 0.140 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 99 | 0.140 |
Why?
| | Protein Kinases | 1 | 2017 | 337 | 0.140 |
Why?
| | Signal Transduction | 5 | 2017 | 4905 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 405 | 0.140 |
Why?
| | Pharmacogenetics | 1 | 2016 | 150 | 0.140 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 35 | 0.140 |
Why?
| | DNA Copy Number Variations | 4 | 2018 | 143 | 0.140 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2016 | 303 | 0.140 |
Why?
| | Genetic Variation | 1 | 2019 | 825 | 0.130 |
Why?
| | Paresis | 1 | 2014 | 20 | 0.130 |
Why?
| | Deoxycytidine | 1 | 2015 | 146 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1543 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2019 | 11727 | 0.130 |
Why?
| | Lung Transplantation | 1 | 2016 | 311 | 0.130 |
Why?
| | Multimodal Imaging | 1 | 2015 | 102 | 0.130 |
Why?
| | Alternative Splicing | 3 | 2017 | 208 | 0.130 |
Why?
| | Speech Disorders | 1 | 2014 | 42 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 137 | 0.130 |
Why?
| | Sarcoma | 1 | 2015 | 132 | 0.130 |
Why?
| | Health Care Surveys | 1 | 2016 | 586 | 0.130 |
Why?
| | Receptor, trkA | 1 | 2013 | 25 | 0.130 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1048 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 66 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2020 | 1092 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 369 | 0.130 |
Why?
| | Microscopy, Electron | 1 | 2014 | 446 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 1002 | 0.120 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 102 | 0.120 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 79 | 0.120 |
Why?
| | Graft Rejection | 1 | 2016 | 591 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2015 | 198 | 0.120 |
Why?
| | Autophagy | 1 | 2017 | 317 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1200 | 0.120 |
Why?
| | Headache | 1 | 2014 | 154 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 306 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 2187 | 0.120 |
Why?
| | Tissue Fixation | 1 | 2012 | 30 | 0.120 |
Why?
| | Societies, Medical | 4 | 2018 | 764 | 0.120 |
Why?
| | Gene Amplification | 3 | 2019 | 106 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 195 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 1090 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1997 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 697 | 0.110 |
Why?
| | Disease Progression | 5 | 2018 | 2494 | 0.110 |
Why?
| | Mutation Rate | 1 | 2011 | 22 | 0.110 |
Why?
| | Lung | 4 | 2015 | 3580 | 0.110 |
Why?
| | Translocation, Genetic | 1 | 2012 | 118 | 0.110 |
Why?
| | Algorithms | 1 | 2019 | 1519 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 397 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2397 | 0.110 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 76 | 0.110 |
Why?
| | Teratoma | 1 | 2011 | 91 | 0.100 |
Why?
| | Specimen Handling | 1 | 2012 | 172 | 0.100 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 205 | 0.100 |
Why?
| | Terminology as Topic | 1 | 2012 | 202 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2017 | 1016 | 0.100 |
Why?
| | Genome, Human | 1 | 2012 | 303 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1934 | 0.100 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1426 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 779 | 0.100 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 68 | 0.090 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 224 | 0.090 |
Why?
| | Telomere | 3 | 2000 | 203 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2012 | 330 | 0.090 |
Why?
| | Phosphorylation | 1 | 2014 | 1734 | 0.090 |
Why?
| | Survival Rate | 4 | 2019 | 1862 | 0.090 |
Why?
| | Disease-Free Survival | 3 | 2016 | 686 | 0.090 |
Why?
| | Medical Oncology | 2 | 2022 | 209 | 0.090 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 15 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2015 | 358 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 26 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 728 | 0.090 |
Why?
| | Heart Neoplasms | 1 | 2008 | 44 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1419 | 0.090 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 189 | 0.080 |
Why?
| | Adolescent | 6 | 2019 | 18712 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4959 | 0.080 |
Why?
| | DNA | 1 | 2014 | 1357 | 0.080 |
Why?
| | Workflow | 2 | 2017 | 112 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2940 | 0.080 |
Why?
| | Prospective Studies | 1 | 2017 | 6324 | 0.080 |
Why?
| | Internship and Residency | 1 | 2016 | 991 | 0.070 |
Why?
| | Eye Neoplasms | 1 | 2005 | 14 | 0.070 |
Why?
| | Mental Disorders | 1 | 2014 | 954 | 0.070 |
Why?
| | Immunophenotyping | 1 | 2005 | 297 | 0.070 |
Why?
| | Administration, Oral | 2 | 2018 | 798 | 0.060 |
Why?
| | Genes, ras | 2 | 2015 | 99 | 0.060 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 44 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 348 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3157 | 0.060 |
Why?
| | Blotting, Western | 4 | 2015 | 1294 | 0.060 |
Why?
| | Cell Cycle | 2 | 2012 | 590 | 0.060 |
Why?
| | Cell Survival | 2 | 2017 | 1139 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 129 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 1005 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 370 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 318 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1582 | 0.050 |
Why?
| | Models, Molecular | 2 | 2018 | 1546 | 0.050 |
Why?
| | Standard of Care | 1 | 2020 | 87 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 425 | 0.050 |
Why?
| | Base Sequence | 3 | 2017 | 2280 | 0.050 |
Why?
| | Catalytic Domain | 4 | 2000 | 199 | 0.050 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 52 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2002 | 611 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 192 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5026 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 58 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 36 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 31 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 45 | 0.040 |
Why?
| | Child | 5 | 2015 | 17937 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 116 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 7041 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 97 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 123 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 23 | 0.040 |
Why?
| | Breast | 1 | 2018 | 148 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2930 | 0.040 |
Why?
| | Diarrhea | 1 | 2018 | 178 | 0.040 |
Why?
| | A549 Cells | 1 | 2017 | 55 | 0.040 |
Why?
| | Quality Control | 1 | 2017 | 166 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2017 | 62 | 0.040 |
Why?
| | Pathology, Surgical | 1 | 2016 | 10 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 553 | 0.040 |
Why?
| | Fatigue | 1 | 2018 | 303 | 0.040 |
Why?
| | Centrosome | 1 | 2016 | 59 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 3014 | 0.040 |
Why?
| | Carcinoma | 2 | 2012 | 207 | 0.040 |
Why?
| | Drug Synergism | 1 | 2017 | 359 | 0.040 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 7 | 0.040 |
Why?
| | Consensus | 1 | 2018 | 461 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2018 | 291 | 0.040 |
Why?
| | Child, Preschool | 3 | 2015 | 9680 | 0.040 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 20 | 0.040 |
Why?
| | Lamin Type A | 1 | 2015 | 39 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 126 | 0.040 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 166 | 0.040 |
Why?
| | Mice, Nude | 1 | 2017 | 696 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 74 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 86 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1463 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 236 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 649 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1607 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 735 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 654 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 990 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 132 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 372 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 14 | 0.030 |
Why?
| | beta Catenin | 1 | 2015 | 226 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 164 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 200 | 0.030 |
Why?
| | Animals | 5 | 2019 | 34755 | 0.030 |
Why?
| | Syndecan-4 | 1 | 2012 | 9 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 809 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1166 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 685 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 126 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 458 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 605 | 0.030 |
Why?
| | Bone and Bones | 1 | 2015 | 258 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2015 | 413 | 0.030 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 18 | 0.030 |
Why?
| | Incidence | 1 | 2018 | 2456 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2015 | 336 | 0.030 |
Why?
| | Mice | 2 | 2019 | 15478 | 0.030 |
Why?
| | Infant | 2 | 2015 | 8124 | 0.030 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 106 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 313 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 417 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 387 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 243 | 0.030 |
Why?
| | Bronchoscopy | 1 | 2012 | 243 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1752 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 17 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 95 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 929 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1194 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 583 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 882 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1977 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 321 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 20 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4291 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2676 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 795 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 579 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 110 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1807 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 2861 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1231 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3508 | 0.020 |
Why?
| | Fibroblasts | 2 | 2000 | 869 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2616 | 0.020 |
Why?
| | Transcription Factors | 1 | 2011 | 1623 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2013 | 5076 | 0.020 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 4 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 17 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 97 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 45 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 21 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 288 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 231 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 14 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 49 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 46 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 180 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 175 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 964 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 175 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 172 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 149 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 436 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 463 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1422 | 0.010 |
Why?
| | Skin | 1 | 2000 | 680 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1167 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 957 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|